Overview of Biologic Agents in Pediatric Rheumatology

cocukromatolojisi-5-1-2024

Veysel ÇAMa , Halide Özge BAŞARANa

aHacettepe University Faculty of Medicine, Department of Pediatric Rheumatology, Ankara, Türkiye

ABSTRACT
The pathophysiology of chronic inflammatory rheumatic illnesses has been addressed in a number of research over the past few decades. New treatment targets have been produced as a result of the improved understanding of the etiology of rheumatological illnesses. Biologics are a subset of the class of drugs called disease-modifying antirheumatic drugs (DMARDs). Biological drugs regulate specific responses such as B cell depletion, inhibition of T cell activation, and cytokine functions. Over the past 20 years, biologic agents have been widely used in many rheumatic diseases. New molecules are being used with efficacy in more and more indications. However, safety profiles and adverse events remain a concern. The aim of the review was to evaluate the mechanisms of action, clinical effectiveness, adverse effects and safety of biologic and small molecule drugs used for pediatric rheumatology.
Keywords: Rheumatology; pediatrics

Referanslar

  1. Smolen JS, van der Heijde D, Machold KP, Aletaha D, Landewé R. Proposal for a new nomenclature of disease-modifying antirheumatic drugs. Ann Rheum Dis. 2014;73:3-5. [Crossref]  [PubMed]
  2. Gerriets V, Goyal A, Khaddour K. Tumor Necrosis Factor Inhibitors. StatPearls. Treasure Island (FL): StatPearls Publishing Copyright © 2023, StatPearls Publishing LLC., 2023.
  3. Levy-Clarke G, Jabs DA, Read RW, Rosenbaum JT, Vitale A, Van Gelder RN. Expert panel recommendations for the use of anti-tumor necrosis factor biologic agents in patients with ocular inflammatory disorders. Ophthalmology. 2014;121:785-796.e783. [Crossref]  [PubMed]
  4. Kaneko Y, Takeuchi T. An update on the pathogenic role of IL-6 in rheumatic diseases. Cytokine. 2021;146:155645. [Crossref]  [PubMed]
  5. Eshwar V, Kamath A, Shastry R, Shenoy AK, Kamath P. A Review of the Safety of Interleukin-17A Inhibitor Secukinumab. Pharmaceuticals (Basel). 2022;15. [Crossref]  [PubMed]  [PMC]
  6. Brunner HI, Foeldvari I, Alexeeva E, et al. Secukinumab in enthesitis-related arthritis and juvenile psoriatic arthritis: a randomised, double-blind, placebo-controlled, treatment withdrawal, phase 3 trial. Ann Rheum Dis. 2023;82:154-60. [Crossref]  [PubMed]  [PMC]
  7. Mankikian J, Caille A, Reynaud-Gaubert M, Agier MS, Bermudez J, Bonniaud P, et al; EVER-ILD investigators and the OrphaLung network. Rituximab and mycophenolate mofetil combination in patients with interstitial lung disease (EVER-ILD): a double-blind, randomised, placebo-controlled trial. Eur Respir J. 2023;61(6):2202071. [Crossref]  [PubMed]
  8. Puéchal X, Iudici M, Perrodeau E, Bonnotte B, Lifermann F, Le Gallou T, et al. Rituximab vs Cyclophosphamide Induction Therapy for Patients With Granulomatosis With Polyangiitis. JAMA Netw Open. 2022;5:e2243799. [Crossref]  [PubMed]  [PMC]
  9. Steiger S, Ehreiser L, Anders J, Anders HJ. Biological drugs for systemic lupus erythematosus or active lupus nephritis and rates of infectious complications. Evidence from large clinical trials. Front Immunol. 2022;13:999704. [Crossref]  [PubMed]  [PMC]
  10. Nishi K, Ogura M, Tamai N, Gima M, Ide K, Koinuma G, et al. Successful rituximab treatment for severe rapidly progressive interstitial lung disease with anti-MDA5 antibody-positive juvenile dermatomyositis: a case report and literature review. Pediatr Rheumatol Online J. 2022;20:60. [Crossref]
  11. Goswami RP, Ray A, Chatterjee M, Mukherjee A, Sircar G, Ghosh P. Rituximab in the treatment of systemic sclerosis-related interstitial lung disease: a systematic review and meta-analysis. Rheumatology (Oxford). 2021;60:557-67. [Crossref]  [PubMed]
  12. Plüß M, Piantoni S, Tampe B, Kim AHJ, Korsten P. Belimumab for systemic lupus erythematosus-Focus on lupus nephritis. Hum Vaccin Immunother 2022;18:2072143. [Crossref]  [PubMed]  [PMC]
  13. Rovin BH, Furie R, Teng YKO, Contreras G, Malvar A, Yu X, et al. A secondary analysis of the Belimumab International Study in Lupus Nephritis trial examined effects of belimumab on kidney outcomes and preservation of kidney function in patients with lupus nephritis. Kidney Int. 2022;101(2):403-13. [Crossref]  [PubMed]
  14. Cheng H, Zhang XY, Yang HD, Yu Z, Yan CL, Gao C, et al. Efficacy and safety of belimumab/low-dose cyclophosphamide therapy in moderate-to-severe systemic lupus erythematosus. Front Immunol. 2022;13:911730. [Crossref]  [PubMed]  [PMC]
  15. de Wolff L, van Nimwegen JF, Mossel E, van Zuiden GS, Stel AJ, Majoor KI, et al. Long-term abatacept treatment for 48 weeks in patients with primary Sjögren's syndrome: The open-label extension phase of the ASAP-III trial. Semin Arthritis Rheum. 2022;53:151955. [Crossref]  [PubMed]
  16. Ruperto N, Lovell DJ, Berman A, Anton J, Viola DO, Lauwerys B, et al; Pediatric Rheumatology Collaborative Study Group (PRCSG) and the Paediatric Rheumatology International Trials Organisation (PRINTO). Abatacept as Monotherapy and in Combination With Methotrexate in Patients With Juvenile Idiopathic Arthritis: Analysis of 2 Phase III Trials. J Rheumatol. 2023;50(11):1471-80. [Crossref]  [PubMed]
  17. Han Y, Liu L, Zang B, Liang R, Zhao X, Liu B. Advances in natural products and antibody drugs for SLE: new therapeutic ideas. Front Pharmacol. 2023;14:1235440. [Crossref]  [PubMed]  [PMC]
  18. Baer AN, Gottenberg JE, St Clair EW, Sumida T, Takeuchi T, Seror R, et al. Efficacy and safety of abatacept in active primary Sjögren's syndrome: results of a phase III, randomised, placebo-controlled trial. Ann Rheum Dis. 2021;80:339-48. [Crossref]  [PubMed]  [PMC]
  19. Ghoreschi K, Laurence A, O'Shea JJ. Janus kinases in immune cell signaling. Immunol Rev. 2009;228:273-87. [Crossref]  [PubMed]  [PMC]